The overarching strategic plan of this SPORE is to develop methods for identifying persons at greatest risk for developing lung cancer and then preventing this progression. A second, related component is to understand the """"""""cancer gene anatomy"""""""" required for lung cancer development and then using this information for early detection, prevention, and the selection and/or development of new rational treatments. We have chosen to invest in three central translational research themes: early detection of genetic alterations coupled with chemoprevention in former smokers; identification of persons with an increased inherited risk of developing lung cancer; and developing new methods of smoking cessation by elucidating genetic contributions to nicotine addiction. To achieve these goals our SPORE has assembled clinicians and. basic scientists including medical oncologists, thoracic surgeons, pulmonary physicians, pathologists, molecular geneticists, molecular and cell biologists, epidemiologists, behavioral and psycho-pharmacologists, biostatisticians, and experts in development of new technologies and informatics. The SPORE, brings together two major complementary strengths in lung cancer research involving UT Southwestern Medical Center (UTSW) and M.D. Anderson Cancer Center (UTMDA) in the areas of molecular pathogenesis, genetic epidemiology, early detection, chemoprevention, and smoking cessation/nicotine addiction. This SPORE consists of 5 inter-related projects and 3 supporting Cores. The projects are: I. Gene-Discovery: Identification of 3p Recessive Oncogenes; 2. Genetic Susceptibility; 3. Molecular Early Detection; 4. Chemoprevention in Former Smokers; and 5. Smoking Cessation and the Genetics of Nicotine Addiction. The Cores are: Administrative (A); Pathology and Tissue Resources (B); and Biostatistics/Informatics (C). All of the scientific projects are: translational in nature; focus on human lung cancer; arose out of conjoint planning between UTSW and UTMDA and involve scientists from both institutions as Co-investigators; interact with the other projects; include basic and clinical investigators; and utilize Core resources. Innovative Developmental and Career Development Projects include new methods for gene discovery and therapeutics development. Achievement of the aims and objectives of this proposal will result in a major decrease in the incidence, morbidity and mortality of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA070907-05S6
Application #
6501631
Study Section
Special Emphasis Panel (ZCA1 (M1))
Program Officer
Ujhazy, Peter
Project Start
1996-09-30
Project End
2003-04-30
Budget Start
2000-09-01
Budget End
2003-04-30
Support Year
5
Fiscal Year
2001
Total Cost
$2,497,516
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Akbay, Esra A; Kim, James (2018) Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 7:464-486
Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49
Tan, Xiaochao; Banerjee, Priyam; Liu, Xin et al. (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128:1267-1282
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Skoulidis, Ferdinandos; Goldberg, Michael E; Greenawalt, Danielle M et al. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8:822-835
Zhou, Xiaorong; Padanad, Mahesh S; Evers, Bret M et al. (2018) Modulation of Mutant KrasG12D -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function. Mol Cancer Res :
Ferdosi, Shadi; Rehder, Douglas S; Maranian, Paul et al. (2018) Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, ?1-4 Branching, ?1-6 Branching, and ?2-6 Sialylation in Cancer. J Proteome Res 17:543-558
Pietanza, M Catherine; Waqar, Saiama N; Krug, Lee M et al. (2018) Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36:2386-2394
Abrams, Zachary B; Zucker, Mark; Wang, Min et al. (2018) Thirty biologically interpretable clusters of transcription factors distinguish cancer type. BMC Genomics 19:738

Showing the most recent 10 out of 1059 publications